£1m in seed funding raised by Kuano
Kuano closes its £1m seed round, led by ACF Investors. O2h Ventures and a syndicate of angel investors based in Cambridge, London and the U.S. Read more
Kuano graduates from Creative Destruction Lab Accelerator
Kuano is an official graduate of the Quantum stream of Creative Destruction Lab (CDL), one of the world’s top deep tech accelerators
Kuano to collaborate with the Alzheimer’s Research UK DDI
Our collaboration has the potential to expand the portfolio of chemotypes being explored targeting NOTUM in the treatment of dementia.
Kuano appoints Dr. Andy Mulvaney as Non-Executive Director
Andy is a seasoned industry executive and, in addition to hands-on experience of contributing to the formation and development of a highly successful biotech, Summit Therapeutics, Inc.(NASDAQ:SMMT), brings broad corporate, business and operational development experience to Kuano.
Kuano raises pre-seed funding
“We are very pleased to back Kuano in this venture. Being able to more accurately understand and predict subtle changes around enzyme’s active sites could unlock faster opportunities to push inhibitors for difficult drug targets through discovery and development.” Sunil Shah, CEO o2h
Kuano wins InnovateUK grant
InnovateUK has awarded Kuano a “Business-led innovation in response to global disruption grant to build a combined AI and modelling service for rapid response drug design.
Kuano joins the COVID-19 HPC Consortium
Kuano has been selected to join the COVID-19 High Performance Computing (HPC) Consortium and will work with AWS to identify novel COVID-19 drugs using a combination of virtual screening and machine learning approaches.
Kuano becomes a member of CrowdHelix
We are excited to have become an SME member of CrowdHelix, a EU and UK focussed community of over 4030 SMEs and research & innovation professionals working together to enable collaborations and partnerships.
CompBioMed partners with Kuano
Kuano has joined CompBioMed, a European HPC Centre of Excellence as an associate partner. CompBioMed brings together leading academic institutions (including UCL, University of Oxford and University of Edinburgh in the UK), leading HPC centres across Europe and industry partners such as Janssen, AstraZeneca and GSK.